Thema: CH0012005267
Novartis, CH0012005267
Novartis AG CH0012005267 – Pharmatechniker bedient eine industrielle Tablettenpresse in dokumentarischer Schwarzweißfotografie - Foto: THN
Novartis stock heads into Boston cell and gene therapy conference
Novartis stock enters a Boston conference focused on cell and gene therapies. Terrapinn lists a Novartis research executive among the speakers.
ad-hoc-news.de, 04.11.26 18:14 Uhr
Novartis, CH0012005267
Novartis stock enters Boston week with research speaker ...
Novartis stock heads into a Boston conference focused on cell and gene therapies. A Novartis research executive is listed among the speakers.
ad-hoc-news.de, 03.11.26 18:11 Uhr
Novartis, CH0012005267
Novartis stock enters Boston advanced-therapies week
Novartis stock enters a key week for advanced therapies as an industry event opens in Boston. The program covers cell and gene therapy development.
ad-hoc-news.de, 02.11.26 09:49 Uhr
Novartis, CH0012005267
Novartis stock heads into Boston advanced-therapies event ...
Novartis stock enters a week focused on advanced therapies in Boston. The event puts cell and gene therapy development in focus.
ad-hoc-news.de, 01.11.26 17:11 Uhr
Novartis, CH0012005267
Novartis stock faces mixed signals as guidance improves
Novartis stock faces mixed signals after stronger core earnings and a higher outlook. Pipeline progress contrasts with major trial-related charges.
ad-hoc-news.de, 31.10.26 10:36 Uhr
Novartis, CH0012005267
Novartis stock gains as Q3 core profit lifts 2026 outlook ...
Novartis stock follows stronger core earnings after the drugmaker raised its 2026 profit outlook. A major impairment weighed on reported profit.
ad-hoc-news.de, 30.10.26 16:01 Uhr
Novartis, CH0012005267
Novartis stock gets outlook lift as core earnings advance ...
Novartis stock follows a stronger core earnings outlook after the pharmaceutical group reported third-quarter growth. A major impairment clouded reported profit.
ad-hoc-news.de, 30.10.26 09:47 Uhr
Novartis, CH0012005267
Novartis stock reaches EUR 143.81 after outlook upgrade
Novartis stock extends its post-results advance as stronger core earnings support the outlook. Pipeline setbacks keep investor sentiment divided.
ad-hoc-news.de, 29.10.26 17:51 Uhr
Novartis, CH0012005267
Novartis raises 2026 profit outlook. Novartis stock gains ...
Sales rose 4.00 percent to USD 14.52 billion for July-September. Novartis stock costs EUR 139.69 on October 27, 2026, up 1.89 percent versus Xetra close.
ad-hoc-news.de, 27.10.26 16:51 Uhr
Novartis, CH0012005267
Novartis raises 2026 core income guidance for Novartis stock ...
